

## TECHNICAL SHEET IDYLLA™ BRAF MUTATION ASSAY



The **Idylla™ BRAF Mutation Assay**, performed on the Biocartis Idylla™ System, is a molecular assay for the qualitative detection of **V600E/E2/D** and **V600K/R/M** mutations in **codon 600** of the BRAF gene.

The **Idylla™ BRAF Mutation Assay**, from **sample-to-result**, starts with formalin-fixed paraffin-embedded (FFPE) tissue to liberate DNA for subsequent real-time PCR amplification and detection.

### FEATURES

#### BRAF mutation detection

	BRAF V600E	(c.1799T>A)
	BRAF V600E2	(c.1799_1800delinsAA)
	BRAF V600D	(c.1799_1800delinsAT; c.1799_1800delinsAC)
<b>Codon 600</b>	BRAF V600K	(c.1798_1799delinsAA)
	BRAF V600R	(c.1798_1799delinsAG)
	BRAF V600M	(c.1798G>A)
	BRAF Wild Type	(c.1799T)

RNaseP (acting as Sample Processing Control)

#### Specimen requirements

Sample Type	FFPE tissue sections (5 to 10 µm)
Neoplastic cells	≥50%, if less macrodissection is required
Tissue area	50-600 mm <sup>2</sup> (5 µm) 25-300 mm <sup>2</sup> (10 µm)

#### Total turnaround time

Time	90 minutes
------	------------

#### Result Reporting

Report	Qualitative genotype call
--------	---------------------------



Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and the Idylla trademark and logo are used trademarks owned by Biocartis. Idylla™ platform is a CE marked IVD in Europe and Idylla™ BRAF Mutation Assay is for Research Use Only. Not for use in diagnostic procedures. Idylla™ is available for sale in EU, USA and many other countries. Please check availability with the local Biocartis representative. © Biocartis, October 2021